Triazole derivatives capable of affecting calcium ion channels of tumor cells, preparation method and application thereof

A calcium ion channel, tumor cell technology, applied in the field of triazole derivatives and their preparation, can solve the problems of patients being susceptible to various tumors, reducing human immunity, etc., and achieve significant application value, improve yield, and improve response. Yield effect
CN113527334BActive Publication Date: 2022-04-29JINAN ASIA PHARMA TECH +1
2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
JINAN ASIA PHARMA TECH
Publication Date
2022-04-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical chemical synthesis, in particular to a triazole derivative capable of affecting calcium ion channels of tumor cells, a preparation method and application thereof. The present invention uses dolutegravir as a lead compound, utilizes the principle of drug splicing, and through a click reaction, changes the benzyl group in the dolutegravir structure into a 1,2,3-triazole structure to obtain a new compound, It can inhibit the growth of tumor cells by affecting calcium ion channels in tumor cells, and has significant application value.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of pharmaceutical chemical synthesis, in particular to a triazole derivative capable of affecting calcium ion channels of tumor cells, a preparation method and application thereof. Background technique

[0002] Dolutegravir is a safe and efficient HIV integrase inhibitor with high genetic barrier and good pharmacokinetic properties. It was developed by GlaxoSmithKline in the United States and approved by the Food and Drug Administration FDA in 2013 listed. Dolutegravir blocks the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration by binding to the integrase active site. The drug is only taken once a day. For the treatment of patients with HIV-1 infection for the first time, the efficacy is equivalent to that of Raltegravir taken twice a day, and it has high safety and strong anti-drug resistance properties. Dolutegravir Wei, as an FDA priority review drug, is expected to reach US$2....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More